Deemed exercise of options. It is agreed that, subject to ▇▇▇▇▇▇▇ ▇▇.▇, ▇▇▇▇▇▇ shall be deemed to have exercised, on certain dates, Additional Technology Antigen-Exclusive Commercial Options against certain Antigens, Additional Technology Exclusive Antibody Commercial Options for certain Non-Exclusive Antigens and Additional Technology Research Options for certain Research Antigens, in each case as set forth in Exhibit F of this Agreement.
Appears in 2 contracts
Sources: Evaluation and Commercialization Agreement (Genmab a/S), Evaluation and Commercialization Agreement (Genmab a/S)